56届美国血液学年会报告,圣弗朗西斯科,2014年12月4日-9日

Report on the 56th ASH Annual Meeting, San Francisco, 4–9 December 2014

Abstract
The 56th annual ASH (American Society of Haematology) meeting was held in San Francisco (CA). More than 3,000 abstracts were selected for presentation due to the huge amount of information from basic science to clinical experience. The future direction in haematoncology is targeted therapies for most diseases; for instance, anti-PD-1 and CAR-T cells in lymphoproliferative disorders and novel immunomodulatory agents active in the contest of bone marrow milieu in multiple myeloma. On the other hand, in aggressive haematological diseases (AML, ALL), clinical studies demonstrated the feasibility of a more intensive chemotherapy approach in older patients.
Keywords: chimeric antigen receptors, intensive chemotherapy, PD-1 inhibitors, target therapy

56届美国血液学年会报告,圣弗朗西斯科,2014年12月4日-9日

摘要:
56届美国血液协会年会在圣弗朗西斯科举办。由于从基础研究到临床试验需要大量的信息，所以会议上选择了超过3000篇摘要。未来的研究方向是靶向治疗这些肿瘤疾病：例如，抗PD-1和CAR-T细胞治疗在淋巴组织增生性疾病上的应用，以及新型免疫调节剂在多发性骨髓瘤骨髓环境中的作用。另一方面，在侵袭性血液病（AML，ALL），临床研究表明在老年患者中更密集的化疗方法的可行性。

关键词：嵌合抗原受体，密集的化疗，PD-1抑制剂，靶向治疗
出自爱康得